A 29 years-old, primigravida, during antenatal evaluation was referred for Hemoglobin capillary electrophoresis. She was a resident of Delhi and was asymptomatic hitherto. Her physical examination was essentially normal. The blood profile showed hemoglobin (Hb) concentration of 11.3 g/dL, red cell mean corpuscular volume 81.2 fL, mean corpuscular hemoglobin 26.2 pg, mean corpuscular hemoglobin concentration 32.3 g/dL, total red cell count of 4.31 × 106/µL and red cell distribution width of 14.9% (CV). The hemoglobin capillary zone electrophoresis (Minicap Sebia hemoglobin capillary electrophoresis) showed Hb A 0.4%, Hb A2 2.2% and Hb D 97.4% with a bifid peak in D zone (zone D) (Fig. 1a). To further characterize this bifid peak, Hb HPLC (Biorad variant II) was done which showed Hb A 4.10%, Hb D 45.60% and Hb A2 (D Iran) 46.20% with retention times 2.150, 3.620 and 4.002 respectively (Fig. 1b) thereby confirming the patient to be a compound heterozygote of Hb D-Iran and Hb D-Punjab. Her family Hb HPLC study showed her father was heterozygous Hb D-Iran (Fig. 1c), mother to be heterozygous Hb D-Punjab (Fig. 1d) while husband’s Hb HPLC was normal (not shown here). No further fetal testing was done due to insignificant clinical nature of these hemoglobinopathies. This case brings out a rare compound heterozygous encountered in routine screening and further reiterates the significance of combining two modalities of diagnosis in defining hemoglobinopathies.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.